Petros Family Wealth LLC boosted its position in shares of Stryker Corporation (NYSE:SYK – Free Report) by 3.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,536 shares of the medical technology company’s stock after buying an additional 167 shares during the period. Stryker makes up approximately 1.6% of Petros Family Wealth LLC’s investment portfolio, making the stock its 15th largest position. Petros Family Wealth LLC’s holdings in Stryker were worth $1,794,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Consolidated Portfolio Review Corp boosted its holdings in Stryker by 4.2% in the second quarter. Consolidated Portfolio Review Corp now owns 648 shares of the medical technology company’s stock valued at $256,000 after acquiring an additional 26 shares during the last quarter. Sunflower Bank N.A. raised its holdings in Stryker by 4.0% during the second quarter. Sunflower Bank N.A. now owns 696 shares of the medical technology company’s stock worth $275,000 after buying an additional 27 shares during the last quarter. Pitti Group Wealth Management LLC lifted its position in Stryker by 3.2% in the 2nd quarter. Pitti Group Wealth Management LLC now owns 861 shares of the medical technology company’s stock valued at $341,000 after acquiring an additional 27 shares in the last quarter. Continuum Advisory LLC boosted its position in shares of Stryker by 5.8% during the first quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company’s stock valued at $198,000 after buying an additional 29 shares during the last quarter. Finally, Oakworth Capital Inc. raised its holdings in shares of Stryker by 0.5% in the first quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company’s stock valued at $2,283,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.
Stryker Price Performance
SYK stock opened at $370.59 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. The company has a market capitalization of $141.68 billion, a PE ratio of 49.08, a price-to-earnings-growth ratio of 2.67 and a beta of 0.94. The company’s fifty day moving average price is $382.81 and its 200-day moving average price is $378.96. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.
Stryker Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be issued a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.
Analyst Upgrades and Downgrades
SYK has been the topic of a number of research reports. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a report on Monday, July 14th. Redburn Partners set a $420.00 target price on shares of Stryker in a research note on Thursday, September 18th. Needham & Company LLC lifted their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Stryker in a research note on Saturday, September 27th. Finally, Truist Financial set a $415.00 price target on shares of Stryker and gave the company a “hold” rating in a research report on Monday, August 4th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Stryker presently has an average rating of “Moderate Buy” and a consensus price target of $430.33.
Check Out Our Latest Stock Analysis on SYK
Insider Activity at Stryker
In related news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. Insiders own 5.20% of the company’s stock.
About Stryker
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Articles
- Five stocks we like better than Stryker
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- 3 Defense Stocks Surging as Ukraine Tensions Deepen
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Starbucks Stock Slumps; This Competitor Shows Strength
- Why Invest in 5G? How to Invest in 5G Stocks
- The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.